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1 |  INTRODUCTION
Marfan syndrome (MFS; MIM 154700) is an autosomal 
dominant connective tissue disorder causing skeletal, 
ocular, and cardiovascular abnormalities (Marfan, 1896). 
Diagnosis of MFS is now standardized through the revised 
Ghent criteria (Loeys et al., 2010); using these criteria, the 
prevalence of MFS is 0.02%–0.03% (Judge & Dietz, 2005). 
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Abstract
Background: Marfan syndrome (MFS) is a dominant monogenic disorder caused by 
mutations in fibrillin 1 (FBN1). Rarely, compound heterozygosity for FBN1 muta-
tions has been described.
Methods: A large kindred with MFS was assessed clinically over decades, and ge-
netically using exome and/or Sanger sequencing.
Results: A previously identified FBN1 missense variant (p.Tyr754Cys) was con-
firmed in all subjects with MFS. An additional variant (p.Met2273Thr), previously 
associated with incomplete MFS, was identified in three siblings. These three com-
pound heterozygous individuals had aortic dilatation at early age (all <30 years): one 
also had cerebral and ocular aneurysms; and one, who had undergone surgical repair 
aged 18 years, died from aortic dissection at 31 years. In contrast, their heterozygous 
father (p.Tyr754Cys) with MFS died at 57  years (myocardial infarction) without 
requiring surgical intervention and one heterozygous (p.Tyr754Cys) sibling has aor-
tic dilatation presenting >40 years but not requiring surgical intervention. Another 
heterozygous (p.Tyr754Cys) sibling did require aortic root repair (28  years). The 
heterozygous (p.Met2273Thr) mother had aortic dilatation diagnosed at age 68 years 
but has not required surgical repair.
Conclusion: Although compound heterozygosity or homozygosity is rare in MFS, 
it should be considered when there is an unusually severe phenotype in a subset of 
family members.
K E Y W O R D S
compound heterozygous, FBN1, fibrillin 1, Marfan syndrome
2 of 7 |   MCINERNEY-LEO Et aL.
MFS is caused by mutations in fibrillin 1 (FBN1; MIM 
134797) (Lee et al., 1991), identified in 90%–95% of indi-
viduals who meet the revised Ghent criteria (acknowledg-
ing that a FBN1 mutation is among those criteria) (Baetens 
et al., 2011; Loeys et al., 2004, 2010; Robinson et al., 2006). 
There are some genotype–phenotype correlations due to the 
location and/or nature of the mutation within FBN1—for 
example, individuals with MFS and aortic involvement are 
much more likely to have truncating or splice site variants 
than individuals without aortic involvement (79% vs. 48%) 
(Baudhuin, Kotzer, & Lagerstedt, 2015); loss of function 
mutations within exons 24–32 are associated with neona-
tal and severe adult forms of MFS; and individuals with 
ectopia lentis are more likely to have a missense mutation 
affecting a cysteine residue than those individuals without 
(71% vs. 52%) (Faivre et al., 2007; Rommel et al., 2005). 
However, these correlations are modest; and overall, there 
is marked phenotypic variability between individuals with 
the same mutation, both inter- and intrafamilially (Dietz & 
Pyeritz, 1995; Dietz et al., 1992).
Here we report a large family with MFS and variably se-
vere phenotype, at least part of which may be due to com-
pound heterozygosity for FBN1 mutations.
2 |  MATERIALS AND METHODS
2.1 | Ethical clearance
This study was approved by The University of Queensland 
Human Research Ethics Committee (UQ #2011000876). All 
individuals provided written informed consent.
2.2 | Participants
Members of a large family with MFS were recruited to a 
study using massive parallel sequencing in genetic disor-
ders associated with bone dysplasias. The pedigree of this 
family has been previously published (Summers et al., 
2004). Detailed clinical information was obtained from 
history, physical examination (including ophthalmology 
assessment), echocardiogram, and medical records, with 
all individuals with MFS evaluated every 3–4 years, over 
decades.
2.3 | Whole-exome sequencing
DNA was extracted from saliva or blood. A subset of family 
members from an extended pedigree (Summers et al., 2004) 
underwent whole-exome sequencing (WES) to identify vari-
ants in MFS/thoracic aortic aneurysm genes, which could be 
modifying the severity. Libraries were prepared, exomes en-
riched, and sequence data were de-multiplexed, processed, 
aligned, and annotated as described previously (McInerney-
Leo et al., 2016). Good quality, rare (minor allele frequency 
(MAF) <0.05) splice site, and coding variants in FBN1, 
ACTA2, FOXE3, LOX, MAT2A, MFAP5, MYH11, MYLK, 
NOTCH1, PRKG1, SMAD3, TGFB2, TGFB3, TGFBR1, 
and TGFBR2 (Milewicz & Regalado, 2017) were assessed. 
Sanger sequencing was used to verify variants of interest and 
determine genotypes in pedigree members not undergoing 
WES.
3 |  RESULTS
The pedigree is presented in Figure 1. The individuals in 
the present report include a branch of the pedigree (indi-
vidual III-4 and his family) presented in the previous study 
(Summers et al., 2004).
3.1 | WES
An average of 5.42 Gb of sequence per individual was gener-
ated (mean depth of coverage 43-fold). Two nonsynonymous 
coding variants in FBN1 were identified.
A missense variant (NM_000138.5:exon19:c.2261A  > 
G:NP_000129.3:p.Tyr754Cys, rs137854479) was present in 
all individuals diagnosed with MFS (Figure 1), as previously 
reported (Summers et al., 2004). It affects a well-conserved 
base (genomic evolutionary rate profiling (GERP) score 
5.66), and is predicted deleterious by Polyphen (Adzhubei 
et al., 2010), MutationTaster (Schwarz, Cooper, Schuelke, & 
Seelow, 2014), and SIFT (Kumar, Henikoff, & Ng, 2009). 
This replaces a tyrosine with a cysteine in EGF-like 11 
domain (the seventh calcium-binding EGF-like domain) 
(UniProt, 2019), which is likely to impact disulfide bond cre-
ation, and compromise fibrillin-1 protein structure (Schrijver, 
Liu, Brenn, Furthmayr, & Francke, 1999).
A second nonsynonymous variant in FBN1 was also 
identified (NM_000138.5:exon56:c.6818T  >  C:NP_000
129.3:p.Met2273Thr, rs754270535). This variant is rare 
(MAF = 3.18e-5 in gnomAD (Karczewski et al. 2019)) and af-
fects a well-conserved base (GERP 5.91). The altered residue 
lies in the EGF-like 39 domain (the 35th calcium-binding EGF-
like domain) (UniProt, 2019), adjacent to a conserved cysteine, 
and is predicted damaging by MutationTaster (1.0), tolerated by 
SIFT (0.2), and benign by Polyphen (0.87). The variant is listed 
in the UMD-FBN1 database (exon 55 in this database) (Collod-
Beroud et al., 2003), reported from an individual diagnosed 
with incomplete MFS (skeletal and cardiac features of MFS but 
no ocular abnormalities) (Comeglio et al., 2007). The second 
variant was present in three siblings with MFS, each of whom 
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also carried the known family variant, and in their mother, who 
has not been diagnosed with MFS.
The three compound heterozygous cases had collectively 
three children diagnosed with MFS, each carried the previ-
ously identified FBN1 variant (i.e., p.Tyr754Cys) but not the 
newly identified p.Met2273Thr variant.
3.2 | Clinical information
Detailed phenotypes are presented in Table 1.
The father (I-1), who carried the common family variant 
(p.Tyr754Cys), was diagnosed with MFS based on ectopia 
lentis, dilated aorta (not requiring repair), and a known diag-
nosis of MFS in his siblings and offspring (Summers et al., 
2004). He died aged 57 years of a myocardial infarction.
The mother (I-2), who carried the second variant (p.Met-
2273Thr), has not been diagnosed with MFS. She had echo-
cardiography at age 65  years following the diagnosis of 
hypertension, which showed aortic dilatation (>2SD). She 
has no ocular signs. Her skeletal phenotype has not been as-
sessed (including no measurement of arm span to height ratio 
and upper to lower segment ratio). She does not have ectopia 
lentis. She is otherwise well, aged 74 years.
Of their seven children, five have MFS. Three are com-
pound heterozygous (II-3, II-2, and II-7), with early evi-
dence of aortic dilatation (presenting before age 30 years) 
requiring aortic root repair (at ages 31  years, 41  years, 
and 18 years, respectively). II-2 also had cerebral and oc-
ular vasculature aneurysms and II-7 died aged 31  years 
(13 years after aortic root repair) from aortic dilatation and 
dissection. The remaining two individuals with MFS (II-1 
and II-5) carry only the common family variant (p.Tyr-
754Cys). II-1 had aortic dilatation (4  cm diameter at the 
sinus of Valsalva, Z-score 2.61) diagnosed at age 43 years, 
without progression over the next 6 years, and to date, has 
not required surgery (now aged 55 years). II-5 had aortic 
root repair at 28 years; since then, aortic root diameter has 
remained normal requiring no further intervention (now 
aged 49 years). The remaining two children were clinically 
and genetically unaffected.
Three offspring of the three compound heterozygous 
individuals had clinical data and DNA available. All three 
have been diagnosed with MFS. Each carried the common 
family variant (p.Tyr754Cys). They had normal echocar-
diograms when last assessed (at ages 39  years, 11  years, 
and 8 years).
4 |  DISCUSSION
We present three siblings with compound heterozygous FBN1 
mutations, whose vascular phenotype may be more severe 
than other members of the pedigree with a single mutation.
All individuals in this family with diagnosed MFS (all 
of whom have the p.Tyr754Cys variant) have ectopia lentis, 
F I G U R E  1  Pedigree showing segregation of both FBN1 variants
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though the skeletal phenotype is variable, and not all have 
aortic dilatation. The three compound heterozygous indi-
viduals presented with aortic dilatation at an early age and 
required surgical intervention; one died at 31 years of aor-
tic dissection and another had extensive aneurysmic disease, 
including an ocular aneurysm, which has not been reported 
previously in MFS. One of their singly heterozygous siblings 
also required aortic root repair at a young age (28 years); the 
other was diagnosed with aortic dilatation aged 43 years but 
has not required repair, and the three singly heterozygous 
offspring do not have aortic root dilatation (noting that two 
of them are still very young). Additionally, their singly het-
erozygous father did not require surgical intervention. Their 
mother carries a variant previously associated with incom-
plete MFS; however, as far as has been assessed, her pheno-
type does not meet the revised Ghent criteria for MFS and 
appears milder than that previously reported (Comeglio et al., 
2007). She did not have an echocardiogram prior to devel-
oping hypertension. About 4.5% of women with otherwise 
undifferentiated hypertension have aortic dilatation (Covella 
et al. 2014); thus, the significance of her aortic root dilatation 
is unclear.
Compound heterozygosity or homozygosity for FBN1 
mutations in MFS has been reported previously, and a re-
view of all 20 reported individuals from 16 families has 
been published (Arnaud et al., 2017). The phenotype of 
these published cases appears more severe than that of 
their heterozygous parents and/or other family members. 
Relevantly, varying expression of the wild-type FBN1 al-
lele in heterozygous individuals may modify phenotypic 
severity. Lower expression of wild-type FBN1 mRNA was 
associated with a more severe phenotype (increased risk 
of ectopia lentis, pectus deformities, and aortic dilatation) 
with variability in expression postulated from trans-acting 
regulators (Aubart et al., 2015). Individuals with a more 
severe MFS phenotype may have a second variant (patho-
genic or of uncertain significance) in another MFS/thoracic 
aortic aneurysm/cerebral aneurysm gene, for example, 
COL4A1, as demonstrated in nine of 51 severely affected 
cases (Aubart et al., 2018). The limited number of family 
members in our pedigree precludes more definitive conclu-
sions regarding possible additive effects of the second vari-
ant; and unfortunately, we do not have access to fibroblasts 
to assess FBN1 expression.
Of note, neither of the mutations reported here are 
loss-of-cysteine or premature termination codon (PTC) vari-
ants, which are associated with a more severe phenotype 
(Faivre et al., 2007). None of the homozygous cases reported 
to date have loss-of-cysteine or PTC variants, while all of 
the five reported compound heterozygous cases carried either 
a loss-of-cysteine or PTC variant in one allele had a milder 
(non-PTC or non-loss-of-cysteine) missense mutation in 
trans (Arnaud et al., 2017).R
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In conclusion, we report here three individuals with MFS 
and compound heterozygous mutations in FBN1, all of whom 
had severe aneurysmic disease, suggesting a gene dose ef-
fect of FBN1 mutations may contribute to a more severe 
phenotype.
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